carbohydr
epitop
glycotop
structur
divers
occur
varieti
chemic
context
present
surfac
cell
bodi
surfac
pathogen
variou
structur
mode
present
affect
perceiv
process
bodi
dictat
outcom
immun
respons
direct
review
focus
mechan
carbohydr
immun
emphasi
carbohydr
vaccin
develop
protect
encapsul
bacteri
pathogen
discuss
cellular
basi
carbohydr
immun
newli
identifi
glycotop
process
pathway
recognit
capabl
synthet
microarray
technolog
develop
permit
new
experiment
approach
carbohydr
vaccin
develop
explor
interact
immun
system
self
nonself
glycan
articl
focus
primarili
mechan
carbohydr
immun
emphasi
carbohydr
vaccin
develop
prevent
diseas
caus
encapsul
bacteri
pathogen
data
use
recent
technolog
advanc
immunolog
genom
glycom
vaccin
develop
also
present
long
known
bactericid
andor
opson
antibodi
direct
capsular
polysaccharid
ps
glycotop
protect
invas
diseas
caus
encapsul
bacteria
accordingli
vaccin
develop
focus
elicit
antibodi
specif
purifi
microbi
ps
vaccin
use
year
proven
variabl
immunogen
variabl
efficaci
protect
suscept
popul
invas
meningococc
pneumococc
haemophilu
influenza
type
b
hib
diseas
administ
purifi
pss
effect
gener
limit
modest
natur
immun
respons
lack
memori
respons
inabl
stimul
respons
young
children
greatest
risk
seriou
infect
due
encapsul
organ
demonstr
infant
could
produc
protect
anticapsular
antibodi
respons
follow
immun
hib
psprotein
conjug
repres
major
advanc
public
health
laid
groundwork
subsequ
develop
new
conjug
vaccin
effect
pneumococc
heptaval
capsular
ps
conjug
vaccin
develop
licens
unit
state
use
infant
children
use
vaccin
led
signific
reduct
seriou
pneumococc
diseas
caus
pneumococci
express
capsular
serotyp
contain
within
vaccin
vaccin
also
shown
reduc
incid
streptococcu
pneumonia
otiti
media
studi
israel
indic
vaccin
may
impact
favor
reduc
number
antibioticresist
strain
vaccin
popul
howev
emerg
evid
demonstr
serotyp
replac
nonvaccin
capsular
type
may
futur
problem
necessit
chang
vaccin
spectrum
pneumococc
ps
conjug
vaccin
present
undergo
evalu
meningococc
serogroup
ps
unusu
immunogen
infant
young
month
age
administr
repeat
dose
elicit
booster
antibodi
respons
reimmun
year
age
maintain
high
degre
protect
older
children
adult
requir
inject
vaccin
group
meningococci
highli
effect
prevent
diseas
number
region
finland
herd
immun
group
meningococci
induc
vaccin
approxim
onethird
popul
use
vaccin
significantli
reduc
preval
diseas
china
household
contact
vaccin
proven
highli
effect
africa
howev
attempt
prepar
protein
conjug
group
meningococc
capsular
ps
increas
immunogen
group
b
meningococcu
major
caus
seriou
meningococc
diseas
unit
state
group
b
capsular
ps
nonimmunogen
presum
ident
selfantigen
potenti
induct
autoimmun
lack
immunogen
discourag
commerci
develop
psbase
group
b
vaccin
altern
approach
focus
antigen
outer
membran
vesicl
outer
membranevesicl
vaccin
good
efficaci
older
children
adult
howev
data
infant
mix
follow
extens
test
omv
vaccin
prepar
epidem
group
b
strain
new
zealand
provision
licens
vaccin
introduc
popul
attempt
control
epidem
investig
wyeth
oxford
univers
england
studi
detoxifi
meningococc
lipopolysaccharid
conjug
vaccin
inner
core
meningococc
lipopolysaccharid
rel
highli
conserv
use
appropri
conjug
procedur
result
broadli
crossreact
meningococc
lipopolysaccharid
vaccin
meningococc
group
c
ps
conjug
vaccin
proven
excel
vaccin
unit
kingdom
decreas
rate
group
c
diseas
observ
vaccin
conjug
children
vaccin
infanc
month
age
effect
vaccin
decreas
low
level
year
much
smaller
declin
efficaci
infant
vaccin
month
age
suggest
booster
dose
administ
month
age
might
protect
loss
efficaci
recommend
followup
studi
also
demonstr
evid
switch
meningococc
capsular
serogroup
serogroup
c
serogroup
caus
vaccin
pressur
note
except
group
meningococc
ps
children
age
year
gener
unrespons
vaccin
purifi
ps
antigen
one
earli
explan
anergi
infant
lack
relev
psspecif
b
cell
howev
numer
studi
demonstr
insuffici
antibodi
repertoir
account
refractori
infant
ps
vaccin
infant
produc
antip
antibodi
ps
conjug
vaccin
studi
hib
ps
antibodi
repertoir
shown
infant
util
variabl
v
region
gene
use
adult
despit
intens
investig
mechan
underli
unrespons
infant
ps
vaccin
precis
identifi
mechan
like
multifactori
may
involv
lack
express
suffici
costimulatori
molecul
andor
respect
receptor
immatur
dendrit
cell
andor
margin
zone
b
cell
cell
surfac
bodi
replet
glycan
molecul
clear
self
glycotop
function
tolerogen
thu
neg
shape
express
antibodi
repertoir
absenc
antibodi
b
bloodgroup
substanc
individu
express
respect
blood
group
repres
classic
exampl
howev
toler
imperfect
antibodi
selfglycan
structur
present
healthi
subject
infecti
agent
vaccin
express
glycotop
structur
relat
self
glycan
elicit
antibodi
reactiv
self
antigen
exampl
neutral
antibodi
elicit
inactiv
sever
acut
respiratori
syndrom
coronaviru
vaccin
crossreact
human
serum
glycoprotein
asialoorosomucoid
less
clear
role
self
glycan
posit
select
b
cell
repertoir
grow
bodi
evid
indic
posit
select
occur
murineb
cell
develop
involv
select
self
glycoprotein
recent
discoveri
endogen
glycosphingolipid
isoglobotrihexosylceramid
suggest
self
glycan
may
mediat
posit
select
cell
andor
nk
cell
despit
lack
understand
mechan
well
establish
refractori
infant
pss
class
antigen
design
thymusindepend
ti
type
overcom
ps
glycotop
present
context
immunogen
carrier
protein
coupl
protein
thought
convert
glycotop
celldepend
immunogen
immun
ps
proteinconjug
vaccin
like
involv
activ
follicular
b
cell
popul
follicular
b
cell
take
ps
protein
conjug
via
psspecif
bcell
receptor
process
carrier
protein
moieti
present
result
peptid
cell
surfac
major
histocompat
complex
class
ii
molecul
may
engag
peptidespecif
cell
psspecif
b
cell
therebi
receiv
signal
via
cognat
cellb
cell
interact
engag
suffici
activ
differenti
antibodi
secret
cell
germinalcent
format
class
switch
recombin
somat
hypermut
memori
b
cell
gener
celldepend
process
activ
subsequ
stimul
either
psprotein
conjug
multiepitop
ps
differ
carrier
protein
use
formul
psconjug
vaccin
although
thought
convert
glycotop
celldepend
form
possess
dispar
immunolog
properti
exampl
hib
psconjug
vaccin
util
differ
carrier
elicit
distinct
antibodi
popul
discern
idiotyp
avid
analys
furthermor
studi
human
indic
cytokin
respons
elicit
follow
immun
pneumococc
conjug
vaccin
outer
membran
protein
complex
deriv
neisseria
meningitidi
use
carrier
protein
psconjug
vaccin
hib
psconjug
vaccin
outer
membran
protein
complex
carrier
uniqu
capabl
stimul
serum
antihib
psantibodi
respons
infant
singl
immun
contrast
conjug
util
bacteri
toxoid
carrier
usual
elicit
signific
seroconvers
second
immun
properti
outer
membraneprotein
complex
carrier
may
relat
abil
engag
tolllik
thu
carrier
protein
function
sourc
peptid
epitop
permit
deliveri
cell
help
also
possess
mitogen
adjuvantlik
properti
stimul
innat
immun
respons
immunolog
variabl
differ
carrier
increas
use
multival
glycoconjug
util
carrier
protein
gener
concern
potenti
complic
aris
high
carrier
dose
antigen
competit
carrierinduc
epitop
suppress
concern
prompt
search
altern
carrierprotein
strategi
includ
synthesi
peptid
carrier
function
univers
helpercel
epitop
bind
promiscu
human
leukocyt
antigendr
molecul
synthesi
recombin
carrier
protein
contain
string
cell
epitop
deriv
sever
pathogenderiv
antigen
pss
classifi
antigen
basi
abil
stimul
antigenspecif
b
cell
absenc
cell
ps
antigen
natur
multival
repeat
glycotop
structur
engag
suffici
number
b
cell
receptor
result
b
cell
activ
matur
antibodi
secret
inabl
ps
immun
lead
anamnest
respons
suggest
memori
b
cell
gener
type
antigen
stimul
presum
failur
immunogen
associ
mhcii
molecul
recruit
cell
help
although
b
cell
activ
antigen
occur
independ
cell
becom
increasingli
clear
accessori
signal
addit
gener
b
cellreceptor
crosslink
requir
gener
antibodi
respons
antigen
vitro
highli
purifi
b
cell
respond
antigen
accessori
cell
dendrit
cell
macrophag
costimulatori
signal
requir
effect
respons
antigen
addit
mani
antigen
abl
fix
complement
format
complex
vivo
could
facilit
b
cell
activ
provid
costimul
complement
receptor
engag
complement
receptor
lower
antigen
signal
threshold
b
cell
activ
coupl
complement
fragment
enhanc
ps
immunogen
sever
moleculessuch
transmembran
activ
ligand
b
lymphocyt
stimul
tyrosin
kinas
bruton
tyrosin
kinas
phospholipas
identifi
costimulatori
signal
receptor
necessari
gener
antibodi
respons
antigen
review
understand
mechan
molecul
exert
effect
suggest
new
way
enhanc
respons
carbohydratebas
vaccin
also
new
way
suppress
autoimmun
respons
direct
self
glycan
immun
respons
glycotop
present
context
microb
import
understand
carriag
acquisit
natur
acquir
immun
respons
infect
major
older
children
adult
possess
serum
antibodi
specif
plethora
bacteri
capsular
glycotop
antibodi
mediat
protect
immun
presum
exposur
homolog
organ
organ
express
crossreact
glycotop
drive
format
antibodi
natur
antibodi
appear
deriv
memori
b
cell
molecular
analys
adult
pneumococc
antibodi
show
undergon
class
switch
hypermut
find
suggest
exposur
glycotop
present
context
bacteri
surfac
gener
psspecif
b
cell
antibodi
secret
memori
develop
mice
cell
engag
tolllik
adaptor
protein
implic
respons
pneumococc
glycotop
elicit
intact
bacteria
unlik
conjug
vaccin
usual
occur
intramuscular
rout
natur
exposur
occur
predominantli
across
mucos
surfac
thu
understand
induct
natur
immun
mainten
carrier
state
must
take
account
migrat
pattern
secondari
lymphoid
tissu
homeostat
mechan
oper
mucos
surfac
like
bacteria
purifi
ps
glycoconjug
vaccin
address
overlap
well
distinct
subset
b
cell
discuss
follicular
b
cell
probabl
major
subset
activ
psprotein
conjug
wherea
bloodborn
bacteria
ps
antigen
thought
stimul
marginalzon
b
cell
b
cell
mous
marginalzon
b
cell
differ
follicular
b
cell
rapid
prolif
respons
elabor
igm
antibodi
earli
cours
bacteri
infect
suggest
b
cell
repres
innatelik
respons
mediat
immedi
immun
slower
adapt
respons
develop
human
marginalzon
b
cell
express
high
level
suggest
might
well
suit
present
bacteri
deriv
lipid
antigen
human
subpopul
circul
b
cell
phenotyp
marginalzon
b
cell
cell
design
igm
memori
b
cell
express
cellsurfac
igm
memori
cell
marker
v
gene
peripher
blood
igm
memori
b
cell
mutat
recent
report
indic
cell
mobil
respons
ps
vaccin
igm
memori
b
cell
mutat
v
gene
present
patient
hyper
igm
syndrom
lack
function
ligand
interact
find
prompt
suggest
pathway
somat
hypermut
exist
human
tradit
pathway
depend
cell
receptor
interact
anoth
pathway
independ
receptor
interact
molecular
model
xray
crystallograph
studi
verifi
origin
propos
kabat
et
al
antibodycombin
site
recogn
glycotop
exist
either
shallow
groov
deep
cleft
former
bind
intern
epitop
express
along
length
glycan
polym
latter
bind
epitop
nonreduc
end
glycan
chain
glycotop
express
short
oligom
wherea
other
requir
longer
chain
length
express
studi
type
pneumococc
ps
shown
induct
ospon
activ
antibodi
critic
depend
chain
length
express
conform
epitop
similarli
protect
glycotop
type
iii
group
b
streptococc
ps
conform
depend
helic
structur
requir
extend
chain
length
express
thu
antibodi
prepar
short
oligomer
glycotop
may
show
requisit
antigenbind
specif
may
recogn
nativ
capsular
glycotop
mediat
protect
issu
particularli
import
design
vaccin
use
synthet
oligosaccharid
avid
shown
critic
determin
efficaci
anticapsular
antibodi
protect
hib
pneumococcu
meningococcu
variat
antibodi
avid
occur
cours
immun
respons
influenc
vaccin
type
age
structur
basi
avid
variat
studi
detail
human
respons
hib
ps
structur
conserv
canon
combin
site
domin
repertoir
region
combin
site
drastic
impact
hib
psbind
avid
local
area
thought
repres
antigen
contact
site
includ
allel
polymorph
complementar
region
cdr
heavi
chain
v
region
polymorph
light
chain
gener
differenti
jregion
use
util
differ
insert
residu
vj
junction
recent
new
mechan
antibodi
glycotop
recognit
describ
elsewher
monoclon
antibodi
specif
mannos
glycotop
hiv
found
except
high
affin
potent
neutral
activ
numer
viral
isol
xray
crystallograph
analysi
demonstr
fragment
antigen
bind
dimer
possess
bind
site
mannos
determin
two
combin
site
constitut
tradit
site
creat
associ
variabl
heavi
light
chain
domain
addit
site
creat
domain
exchang
vhvh
interfac
capabl
multival
interact
provid
structur
explan
high
avid
antibodi
thu
target
glycotop
addit
protein
epitop
may
worthwhil
strategi
develop
effect
multival
hiv
vaccin
elicit
broadli
neutral
antibodi
respons
molecular
mimicri
major
area
investig
carbohydr
immunolog
numer
report
shown
peptid
bind
carbohydr
combin
site
isol
peptid
librari
review
peptid
show
appar
specif
bind
peptidesequ
depend
usual
limit
combin
site
select
fundament
issu
whether
mimet
present
immunogen
form
abl
elicit
carbohydratespecif
antibodi
respons
studi
suggest
inde
case
peptid
mimic
shown
induc
crossreact
respons
carbohydr
antigen
express
bacteria
fungi
hiv
envelop
protein
tumor
cell
name
mousetumor
challeng
model
immun
dna
construct
encod
mimet
inhibit
tumor
growth
antimimotop
antibodi
block
cell
adhes
hiv
cell
human
dendrit
cell
one
could
imagin
number
advantag
use
peptidyl
mimic
rather
glycotop
includ
eas
synthesi
purif
abil
formul
varieti
way
amen
glycotop
multipl
antigen
peptid
dna
vaccin
abil
engag
cellular
process
activ
pathway
normal
within
capabl
glycotop
dogma
recognit
glycotop
exclus
proven
antibodi
combin
site
overturn
studi
past
decad
demonstr
cell
receptor
abl
recogn
glycotop
present
appropri
mhcbind
context
function
structur
studi
glycopeptid
antigen
demonstr
mhc
molecul
tether
glycopeptid
bind
peptidyl
moieti
mhcbind
pocket
glycotop
directli
engag
cell
receptor
cytotox
cell
respons
carbohydr
antigen
induc
immun
either
natur
occur
synthet
glycopeptid
glycolipid
antigen
also
recogn
cell
nk
cell
via
mechan
molecul
exist
multipl
isoform
structur
relat
mhc
class
molecul
exampl
antigen
includ
mycobacteri
glycolipid
selfderiv
gangliosid
cell
recogn
lipid
antigen
may
util
varieti
cell
receptora
cell
receptorb
chain
addit
nk
cell
express
invari
cell
receptora
chain
pair
variou
b
chain
mous
man
also
recogn
glycosphingolipid
known
agalactosylceramid
glycolipid
origin
identifi
marin
spong
agalactosylceramid
bind
high
affin
potent
immunoregulatori
properti
administr
agalactosylceramid
induc
product
ifng
activ
nk
cell
cell
b
cell
synthet
analogu
agalactosylceramid
potent
protect
activ
murin
model
malaria
melanoma
restrict
cell
may
produc
either
cytokin
respons
could
import
antitumor
antimicrobi
immun
respons
although
precis
role
cell
adapt
immun
respons
requir
studi
evid
suggest
nkt
cell
involv
immun
mycobacterium
tuberculosi
pseudomona
auruginosa
plasmodium
yoelii
trypanosoma
cruzi
francisella
tularensi
review
recent
studi
capsular
ps
bacteriod
fragili
identifi
new
pathway
glycotop
process
present
work
origin
earlier
studi
demonstr
psspecif
cell
involv
protect
sepsi
caus
b
fragili
capsular
ps
b
fragili
pneumococc
capsul
zwitterion
form
helic
structur
ps
capabl
induc
protect
psspecif
cell
antigen
present
celldepend
fashion
effect
depend
zwitterion
charact
ps
b
fragili
ps
process
antigen
present
cell
via
endosomallysozom
pathway
involv
chemic
cleavag
nitric
oxidemedi
mechan
gener
lowmolecular
weight
carbohydr
capabl
bind
mhcii
present
cell
given
divers
glycan
structur
chemic
context
like
addit
carbohydrateprocess
pathway
discov
exampl
ctype
lectin
known
specif
intracellular
adhes
moleculegrab
express
splenic
marginalzon
macrophag
bind
high
affin
pneumococc
type
capsular
ps
mediat
uptak
type
pneumococci
discoveri
foreign
ps
antigen
glycotop
process
endosom
pathway
present
mhci
mhcii
molecul
recogn
cell
endogen
lectin
hold
great
promis
design
new
glycanbas
adjuv
vaccin
tumor
bacteria
parasit
research
carbohydr
immunolog
acceler
develop
new
technolog
carbohydr
microarray
autom
synthes
oligosaccharid
biophys
comput
method
studi
antigenantibodi
interact
carbohydr
microarray
use
investig
lectin
antibodi
specif
identifi
new
lectin
screen
blood
diseas
pattern
identifi
lead
structur
vaccin
design
consortium
function
genom
establish
develop
novel
glycanarray
format
demonstr
applic
profil
specif
wide
varieti
carbohydratebind
molecul
new
technolog
contribut
design
betterdefin
carbohydr
vaccin
serv
essenti
tool
understand
glycom
interact
immun
system
progress
made
develop
chemic
method
instrument
capabl
effici
highcapac
oligosaccharid
synthesi
advanc
appli
basic
research
develop
synthet
carbohydr
vaccin
experiment
vaccin
util
synthet
carbohydr
develop
number
pathogen
includ
pneumonia
vibrio
cholera
shigella
flexneri
plasmodium
falciparum
hib
vaccin
contain
fulli
synthet
oligom
hib
capsular
ps
test
human
demonstr
elicit
function
activ
antibodi
carbohydr
antigen
repres
signific
resourc
develop
vaccin
infecti
agent
particularli
pathogen
tradit
protein
andor
whole
organismbas
approach
success
although
discuss
articl
larg
bodi
work
explor
carbohydratebas
vaccin
elicit
humor
cellular
immun
tumor
new
carbohydratebas
vaccin
develop
pathogen
hiv
malaria
might
expect
see
clinic
trial
evalu
new
adjuv
agalactosylceramid
asid
need
research
need
varieti
resourc
essenti
avail
carbohydr
microarray
appropri
anim
model
includ
primat
model
transgen
mous
platform
enhanc
also
tetram
analyt
chemistri
need
aid
identif
glycolipid
antigen
recogn
infrastructur
need
includ
good
laboratori
practic
resourc
product
synthet
carbohydr
vaccin
test
safeti
vaccin
candid
anim
opportun
ie
comput
capac
model
carbohydr
antigenantibodi
interact
resourc
need
ensur
complianc
regulatori
standard
defin
chemic
composit
structur
abil
manufactur
consist
physic
chemic
characterist
lack
inher
toxic
capabl
induc
protect
immun
respons
becom
increasingli
appar
variou
structur
mode
glycotop
present
affect
perceiv
process
bodi
dictat
outcom
immun
respons
direct
new
glycotopeprocess
pathway
recognit
capabl
identifi
signal
molecul
involv
cell
activ
elucid
new
synthet
microarray
technolog
develop
permit
new
experiment
approach
explor
interact
immun
system
self
nonself
glycan
discoveri
expect
translat
new
therapeut
vaccin
combat
diseas
improv
human
health
